For this position, the recruiting organisation is Eberhard Karls University of Tübingen in Germany. The selected candidate will be employed within the POLARIS consortium and will be academically enrolled through Eberhard Karls University of Tübingen, where the PhD degree will be pursued in a relevant discipline.

Eberhard Karls University of Tübingen
Eberhard Karls University of Tübingen is a research-intensive university with strong expertise in rare neurological disorders, clinical translation and biomarker research. Within POLARIS, Tübingen contributes expertise in leukodystrophies, quantitative clinical outcomes and biomarker analysis, helping to connect preclinical innovation with clinically meaningful monitoring strategies.
This doctoral project focuses on the development of liquid biomarkers for leukodystrophies.
The candidate will contribute to the development and validation of biomarker panels designed to support diagnosis, newborn-screening follow-up and the monitoring of emerging therapies, including gene and lipid-nanoparticle therapies. The project combines biomarker discovery with translational clinical relevance, linking molecular readouts to disease monitoring and treatment response.
In this project, the candidate will work with patient samples and iPSC-derived human disease models to identify disease-related molecular signatures. The work is expected to integrate multi-omics data, including metabolomics, lipidomics, proteomics and genomics, and to combine these datasets using statistical and machine-learning approaches. Established biomarkers such as neurofilament light chain (NfL) and GFAP will provide biological reference points for identifying disease-specific signatures and evaluating their relevance for treatment monitoring.
The candidate will work closely with researchers in human genetics, computational biology and clinical neurology and will collaborate with POLARIS partners across Europe. Planned secondments will provide experience in omics data generation and biomarker development in industrial and regulatory settings, including a placement at Orchard Therapeutics. A secondment with the European Leukodystrophy Association (ELA) will offer the opportunity to engage with patients and families and to better understand the priorities of affected communities.
The position is based in Tübingen, Germany, with academic enrolment through Eberhard Karls University of Tübingen and full participation in the broader POLARIS doctoral training programme.
Important, strict eligibility criteria according to MARIE SKLODOWSKA CURIE programs apply to applicants:
- You must not already hold a doctoral degree.
- At the time of the application deadline, you must have a Master’s degree and must not have resided or carried out your main activity (work, studies, etc.) in the Netherlands for more than 12 months in the three years prior to the contract start date.
- You will participate in the network-wide training programme of POLARIS, which includes (international) training activities and planned secondments with POLARIS partner organizations throughout the EU.
We are looking for a motivated candidate with a Master’s degree in biomedical sciences, molecular biology, neuroscience, biochemistry, medicine or a related field. You have a strong interest in biomarker research, translational medicine and rare neurological diseases.
Experience with molecular or biochemical techniques, biofluid analysis, omics approaches, clinical research or data analysis is considered an advantage. Experience with iPSC-derived models, multi-omics datasets, biostatistics or machine-learning approaches would be particularly valuable. An interest in connecting laboratory findings with clinically relevant outcome measures and treatment-monitoring strategies is particularly important for this position.
You work accurately and reproducibly, have strong analytical and communication skills, and are able to collaborate effectively in an interdisciplinary and international environment.
- A contract for 12 months, with the intention to extend for a total of 3 years;
- Salary, mobility allowance and benefits according to the applicable MSCA Doctoral Network and host-organisation rules;
- Embedding in the international POLARIS doctoral training network;
- Access to network-wide training activities, secondments and transferable-skills development;
- A challenging and translational research project at the interface of in vivo neuroscience, rare disease biology and preclinical therapy development;
- A collaborative and entrepreneurial working environment;
- An open and supportive team culture with opportunities for scientific and professional development.
Applications for the doctoral positions have now closed. The selection process is currently ongoing, and applications are being reviewed by the recruiting institutions.
POLARIS is now moving into the next phase of its doctoral programme, which will bring together a new cohort of researchers working across disciplines and sectors to advance translational research in leukodystrophies.













